Page 46 - Read Online
P. 46

Genvigir et al. J Transl Genet Genom 2020;4:320-55  I  http://dx.doi.org/10.20517/jtgg.2020.37                                Page 331

             Ref.   [39]  [34]       [40]      [13]       [29]     [35]  [27]       [50]         [22]



             Clinical outcomes  No association of UGT2B7  c.-842G>A, -79G>A and  802C>T variants with AR  No association of UGT2B7   c.-840G>A variant with   gastrointestinal adverse   events  No association of UGT2B7  802C>T variant with AR or   adverse events  UGT2B7 c.-840G allele   was associated with  increased risk of anemia.  No association with AR,   diarrhea, or leukopenia  -  In patients treated non-  depleting antibodies,  UGT2B7 c.-900G allele was  associated









             Pharmacokinetics  No association of   UGT2B7 c.-842G>A,   -79G>A and 802C>T   variants with MPA   exposure (AUC 0-12 )  -  UGT2B7 802T allele was  -  associated with higher   MPA apparent oral   -  -  UGT2B7 IVS1+985AG  genotype was associated  with higher MPA AUC 0-12  -  UGT2B7 c.211G>T   variant was associated   with MPA initial volume   of distribution and   c.211GT genotype was   associated with higher   MPA exposure  -








            Immunosuppressive   regimen  MMF  Cyclosporine  Tacrolimus  Corticosteroids   One-year follow-up  MMF  Cyclosporine  Tacrolimus  Sirolimus  Up to 115-month follow-  up  MMF  Cyclosporine  Tacrolimus Corticosteroids Sixty-day clearance  follow-up  MMF  Cyclosporine  Tacrolimus  mTOR inhibitor   Corticosteroids   One-year follow-up  EC-MPS  Cyclosporine  Corticosteroids  Six-month follow-up  MMF  Tacrolimus  Corticosteroids  MMF  Cyclosporine  Tacrolimus  Siroli











             Population   338 adult patients   256 adult patients   (France)  89 pediatric patients  (France)  218 adult patients   (France)  189 adult patients  (France)  127 adult patients   (China)  284 pediatric and young   adult patients (USA)  118 adult patients   (China)  145 adult patients   (Brazil)









             Study design  Prospective, multicenter  (FDCC  Study)  Retrospective  Prospective, multicenter  Retrospective   (Transgene study)  Prospective, multicenter   (Dominos study)  Prospective  Retrospective (Case-  control) multicenter  Retrospective  Retrospective (Case-  control)







             Allele frequency  c.-842A: 50%  -79A: 2%  802C: 50%  c.-840A: 48%  802T: 48%  802T: 46%  c.-840G: 47%   c.-900G: 29%  IVS1+985G: 5%  c.211T: 14%  -  c.211T: 34%  c.-842G: 37%










             Variant







             Gene
   41   42   43   44   45   46   47   48   49   50   51